Gene Dose of Apolipoprotein E Type 4 Allele and the Risk of Alzheimer's Disease in Late Onset Families
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
The apolipoprotein E type 4 allele ( APOE -ε4) is genetically associated with the common late onset familial and sporadic forms of Alzheimer's disease (AD). Risk for AD increased from 20% to 90% and mean age at onset decreased from 84 to 68 years with increasing number of APOE -ε4 alleles in 42 families with late onset AD. Thus APOE -ε4 gene dose is a major risk factor for late onset AD and, in these families, homozygosity for APOE -ε4 was virtually sufficient to cause AD by age 80.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Common variants of the apolipoprotein E gene (APOE) influence the risk of Alzheimer’s disease: APOE4 is linked to high risk, APOE3 is considered to confer a neutral risk, and APOE2 is associated with relative protection.2–5”
From APOE3 Christchurch Heterozygosity and Autosomal Dominant Alzheimer’s Disease (2024) · cites this paper as [3]
Experimental — accuracy not yet measuredIn the citing paper
“Compared to the most common APOE3/3 genotype, each additional copy of the APOE4 allele is associated with a higher risk of Alzheimer’s dementia and a younger mean age at dementia onset, such that APOE4 homozygotes are at the highest risk”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [3]
In the citing paper
“while the presence of one or two copies of the APOE2 allele is associated with a lower risk of Alzheimer’s dementia and an older mean age at dementia onset1–4.”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [3]
In the citing paper
“such that APOE4 homozygotes are at the highest risk”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [3]
In the citing paper
“Apolipoprotein E (APOE), the major susceptibility gene for late-onset Alzheimer’s disease (AD), has three common alleles (APOE2, 3, and 4), giving rise to six genotypes (APOE2/2, 2/3, 3/3, 2/4, 3/4, and 4/4).”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [3]
91 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Cox, D. R., & Oakes, D. (2018) · Chapman & Hall/CRC eBooks · doi:10.1201/9781315137438 · Cited by 6,234
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Self-citationStrittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268
Self-citationAssociation of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
Self-citationMiller, R. G. (1981) · Cited by 3,336
Regression analysis of multivariate incomplete failure time data by modeling marginal distributions
Wei, L. J., Lin, D. Y., & Weissfeld, L. (1989) · Journal of the American Statistical Association · doi:10.1080/01621459.1989.10478873 · Cited by 1,868
Schmechel, D. E., Saunders, A. M., Strittmatter, W. J., Crain, B. J., Hulette, C. M., Joo, S. H., Pericak-Vance, M. A., Goldgaber, D., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.20.9649 · Cited by 1,525
Self-citationThe Genetic Defect Causing Familial Alzheimer's Disease Maps on Chromosome 21
St George-Hyslop, P. H., Tanzi, R. E., Polinsky, R. J., Haines, J. L., Nee, L., Watkins, P. C., Myers, R. H., Feldman, R. G., Pollen, D., Drachman, D., et al. (1987) · Science · doi:10.1126/science.2880399 · Cited by 1,163
Self-citationNamba, Y., Tomonaga, M., Kawasaki, H., Otomo, E., & Ikeda, K. (1991) · Brain Research · doi:10.1016/0006-8993(91)91092-f · Cited by 1,157
Genetic Linkage Evidence for a Familial Alzheimer's Disease Locus on Chromosome 14
Schellenberg, G. D., Bird, T. D., Wijsman, E. M., Orr, H. T., Anderson, L., Nemens, E., White, J. A., Bonnycastle, L., Weber, J. L., Alonso, M. E., et al. (1992) · Science · doi:10.1126/science.1411576 · Cited by 946
Research works printed but not linked: 3
- SAS/STAT User's Guide Release 6.03 Edition (1988).
- SAS User's Guide: Statistics Version 5 Edition (1985).
- 10.1073/pnas.90.5.1977 · DOI · Paper page
Cited by
Items 701–800 of 1,689
Higher Rates of Decline for Women and Apolipoprotein E ε4 Carriers
Holland, D., Desikan, R. S., Dale, A. M., & McEvoy, L. K. (2013) · American Journal of Neuroradiology · doi:10.3174/ajnr.a3601 · Cited by 219
“The strongest known common genetic risk factor for sporadic AD is the apolipoprotein E (APOE) 4 allele.(16,17) APOE 4 in-”
BackgroundTREM2, microglia, and Alzheimer’s disease.
Qin, Q., Teng, Z., Liu, C., Li, Q., Yin, Y., & Tang, Y. (2021) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2021.111438 · Cited by 219
BONANNI, E., MAESTRI, M., TOGNONI, G., FABBRINI, M., NUCCIARONE, B., MANCA, M. L., GORI, S., IUDICE, A., & MURRI, L. (2005) · Journal of Sleep Research · doi:10.1111/j.1365-2869.2005.00462.x · Cited by 213
Comorbidity of periodontal disease: two sides of the same coin? An introduction for the clinician
Holmstrup, P., Damgaard, C., Olsen, I., Klinge, B., Flyvbjerg, A., Nielsen, C. H., & Hansen, P. R. (2017) · Journal of Oral Microbiology · doi:10.1080/20002297.2017.1332710 · Cited by 205
“allele is considered to be the most important [85].”
BackgroundTransgenic models of Alzheimer’s disease: Learning from animals
Spires, T. L., & Hyman, B. T. (2005) · NeuroRX · doi:10.1602/neurorx.2.3.423 · Cited by 212
Isoaspartate Formation and Neurodegeneration in Alzheimer's Disease
Shimizu, T., Watanabe, A., Ogawara, M., Mori, H., & Shirasawa, T. (2000) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.2000.1955 · Cited by 215
An evolutionary framework for common diseases: the ancestral-susceptibility model
Di Rienzo, A., & Hudson, R. R. (2005) · Trends in Genetics · doi:10.1016/j.tig.2005.08.007 · Cited by 218
“The 34 allele of the gene encoding Apolipoprotein E (APOE), which increases the risk to coronary artery disease [8‐10] and Alzheimer’s disease [ 11 ,12], carries the ancestral allele at two common amino acid polymorphisms.”
BackgroundStaffaroni, A. M., Brown, J. A., Casaletto, K. B., Elahi, F. M., Deng, J., Neuhaus, J., Cobigo, Y., Mumford, P. S., Walters, S., Saloner, R., et al. (2018) · The Journal of Neuroscience · doi:10.1523/jneurosci.3067-17.2018 · Cited by 212
“Although the APOE 4 allele confers risk for AD pathology (Corder et al., 1993), and some studies have shown that allele status affects DMN FC (Filippini et al., 2009; Zheng et al., 2017), studies in older adults have not reported a clear pattern (Sheline et al., 2010a; Machulda et al., 2011;…”
BackgroundGene–environment interactions in Alzheimer disease: the emerging role of epigenetics
Migliore, L., & Coppedè, F. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00714-w · Cited by 217
Cholesterol involvement in the pathogenesis of neurodegenerative diseases
Liu, J.-P., Tang, Y., Zhou, S., Toh, B. H., McLean, C., & Li, H. (2010) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2009.07.013 · Cited by 203
Jossin, Y. (2020) · Biomolecules · doi:10.3390/biom10060964 · Cited by 202
Siemers, E., Skinner, M., Dean, R. A., Gonzales, C., Satterwhite, J., Farlow, M., Ness, D., & May, P. C. (2005) · Clinical Neuropharmacology · doi:10.1097/01.wnf.0000167360.27670.29 · Cited by 216
Neuropsychological Contributions to the Early Identification of Alzheimer’s Disease
Bondi, M. W., Jak, A. J., Delano-Wood, L., Jacobson, M. W., Delis, D. C., & Salmon, D. P. (2008) · Neuropsychology Review · doi:10.1007/s11065-008-9054-1 · Cited by 216
“In addition, the APOE ɛ4 allele located on chromosome 19 is overrepresented in AD and has been identified as the single most important susceptibility gene for the disease (Corder et al. 1993; Saunders et al. 1993; Strittmatter et al. 1993).”
BackgroundTraumatic brain injury and Alzheimer's disease: a review
Van Den Heuvel, C., Thornton, E., & Vink, R. (2007) · Progress in Brain Research · doi:10.1016/s0079-6123(06)61021-2 · Cited by 213
Amyloid-β and Tau at the Crossroads of Alzheimer’s Disease
Gallardo, G., & Holtzman, D. M. (2019) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-32-9358-8_16 · Cited by 198
Poole, S., Singhrao, S. K., Chukkapalli, S., Rivera, M., Velsko, I., Kesavalu, L., & Crean, S. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-140315 · Cited by 215
“The late-onset form of AD is particularly interesting as its aetiology remains unknown despite the known genetic risk factors, including apolipoprotein E (ApoE) gene and its E4 allele inheritance [2, 3].”
Disrupted Small-World Brain Networks in Moderate Alzheimer's Disease: A Resting-State fMRI Study
Zhao, X., Liu, Y., Wang, X., Liu, B., Xi, Q., Guo, Q., Jiang, H., Jiang, T., & Wang, P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033540 · Cited by 215
“It is well known that ApoE4 is a major risk factor for late-onset AD [83].”
BackgroundTrivedi, M. A., Schmitz, T. W., Ries, M. L., Torgerson, B. M., Sager, M. A., Hermann, B. P., Asthana, S., & Johnson, S. C. (2006) · BMC Medicine · doi:10.1186/1741-7015-4-1 · Cited by 209
“The presence of the ε4 allele significantly increases the risk and reduces the age of onset in people with the late-onset form of AD, the most common form of this disorder [1,3,4].”
BackgroundThe polygenic architecture of schizophrenia — rethinking pathogenesis and nosology
Smeland, O. B., Frei, O., Dale, A. M., & Andreassen, O. A. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0364-0 · Cited by 209
Kuusisto, J., Koivisto, K., Kervinen, K., Mykkanen, L., Helkala, E.-L., Vanhanen, M., Hanninen, T., Pyorala, K., Kesaniemi, Y. A., Riekkinen, P., et al. (1994) · BMJ · doi:10.1136/bmj.309.6955.636 · Cited by 204
Smith, M. A. (1998) · International Review of Neurobiology · doi:10.1016/s0074-7742(08)60607-8 · Cited by 194
Analysis of long-lived C. elegans daf-2 mutants using serial analysis of gene expression
Halaschek-Wiener, J., Khattra, J. S., McKay, S., Pouzyrev, A., Stott, J. M., Yang, G. S., Holt, R. A., Jones, S. J. M., Marra, M. A., Brooks-Wilson, A. R., et al. (2005) · Genome Research · doi:10.1101/gr.3274805 · Cited by 209
“Since alterations in lipid metabolism are thought to be associated with aging and aging-related diseases in humans (Keidar et al. 1990; Corder et al. 1993; Cohen et al. 2002), decreased activity of lipid processing pathways may contribute to the observed longevity phenotype in daf-2.”
BackgroundAPOE ε4 allele predicts faster cognitive decline in mild Alzheimer disease
Cosentino, S., Scarmeas, N., Helzner, E., Glymour, M. M., Brandt, J., Albert, M., Blacker, D., & Stern, Y. (2008) · Neurology · doi:10.1212/01.wnl.0000304038.37421.cc · Cited by 214
Wijsman, E. M., Pankratz, N. D., Choi, Y., Rothstein, J. H., Faber, K. M., Cheng, R., Lee, J. H., Bird, T. D., Bennett, D. A., Diaz-Arrastia, R., et al. (2011) · PLoS Genetics · doi:10.1371/journal.pgen.1001308 · Cited by 214
“In contrast to the success in familial EOAD, only one gene, APOE, is an unequivocally established ‘‘susceptibility’’ gene for LOAD [16], with the e4 allele associated with increased risk in a dose-dependent manner and the e2 allele with decreased risk [17].”
ResultThe LEARn model: an epigenetic explanation for idiopathic neurobiological diseases
Lahiri, D. K., Maloney, B., & Zawia, N. H. (2009) · Molecular Psychiatry · doi:10.1038/mp.2009.82 · Cited by 211
Molecular genetics of Alzheimer's disease: An update
Brouwers, N., Sleegers, K., & Van Broeckhoven, C. (2008) · Annals of Medicine · doi:10.1080/07853890802186905 · Cited by 208
“APOE o4 primarily acts by lowering onset age in a dosage-dependent manner, increasing risk 3 times in heterozygotes and 15 times in homozygotes (211).”
BackgroundMild Cognitive Impairment: Diagnosis, Longitudinal Course, and Emerging Treatments
Vega, J. N., & Newhouse, P. A. (2014) · Current Psychiatry Reports · doi:10.1007/s11920-014-0490-8 · Cited by 195
Early-Onset Alzheimer’s Disease: What Is Missing in Research?
Ayodele, T., Rogaeva, E., Kurup, J. T., Beecham, G., & Reitz, C. (2021) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-020-01090-y · Cited by 193
“of LOAD [54, 64], and a five-fold increased risk of EOAD associated with rare SORL1 variants [55, 56], which is comparable to the effect size observed in APOE-e4 carriers [55, 56, 65].”
ResultOxidative stress and neurodegenerative disorders
Sun, A. Y., & Chen, Y.-M. (1998) · Journal of Biomedical Science · doi:10.1007/bf02255928 · Cited by 215
Cognitive Markers Preceding Alzheimer's Dementia in the Healthy Oldest Old
Howieson, D. B., Dame, A., Camicioli, R., Sexton, G., Payami, H., & Kaye, J. A. (1997) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1997.tb03091.x · Cited by 210
The Utility of Cerebral Blood Flow as a Biomarker of Preclinical Alzheimer’s Disease
Hays, C. C., Zlatar, Z. Z., & Wierenga, C. E. (2016) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-015-0261-z · Cited by 213
“Possession of the APOE e4 allele increases AD risk 3–8 fold, in a dose dependent fashion, and significantly lowers the age of disease onset (Saunders et al. 1993; Corder et al. 1993; Coon et al. 2007).”
BackgroundGoedert, M., & Spillantini, M. G. (2017) · Molecular Brain · doi:10.1186/s13041-017-0298-7 · Cited by 213
“APOEε4 is the major risk factor allele for late-onset AD [52].”
BackgroundMolecular links between Alzheimer’s disease and diabetes mellitus
Yang, Y., & Song, W. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.07.009 · Cited by 201
Analysis of sampling techniques for imbalanced data: An n = 648 ADNI study
Dubey, R., Zhou, J., Wang, Y., Thompson, P. M., & Ye, J. (2014) · NeuroImage · doi:10.1016/j.neuroimage.2013.10.005 · Cited by 204
Mitochondria in Neurodegeneration
Lezi, E., & Swerdlow, R. H. (2012) · Advances in Experimental Medicine and Biology · doi:10.1007/978-94-007-2869-1_12 · Cited by 198
Frederiksen, H., Gaist, D., Christian Petersen, H., Hjelmborg, J., McGue, M., Vaupel, J. W., & Christensen, K. (2002) · Genetic Epidemiology · doi:10.1002/gepi.1127 · Cited by 209
“Cognitive functioning and risk of dementia have consistently been shown to be associated with the apolipoprotein-E gene [Corder et al., 1993; Dik et al., 2000], and some early-onset types of dementia are affected by other specific gene variants.”
BackgroundAlzheimer disease: new concepts on its neurobiology and the clinical role imaging will play
Jack, C. R. (2012) · Radiology · doi:10.1148/radiol.12110433 · Cited by 211
Huynh, T.-P. V., Davis, A. A., Ulrich, J. D., & Holtzman, D. M. (2017) · Journal of Lipid Research · doi:10.1194/jlr.r075481 · Cited by 210
Lin, Y.-T., Seo, J., Gao, F., Feldman, H. M., Wen, H.-L., Penney, J., Cam, H. P., Gjoneska, E., Raja, W. K., Cheng, J., et al. (2018) · Neuron · doi:10.1016/j.neuron.2018.06.011 · Cited by 210
APOE ε4 is associated with severity of Lewy body pathology independent of Alzheimer pathology
Dickson, D. W., Heckman, M. G., Murray, M. E., Soto, A. I., Walton, R. L., Diehl, N. N., van Gerpen, J. A., Uitti, R. J., Wszolek, Z. K., Ertekin-Taner, N., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000006212 · Cited by 210
“Entorhinal 2 (0, 6) 7 (1, 20) 14 (3, 27) 2 (1, 5) 8 (3, 16) 18 (4, 40) 3 (0, 10) 8 (1, 35) 22 (4, 45)”
Bertrand, P., Poirier, J., Oda, T., Finch, C. E., & Pasinetti, G. M. (1995) · Molecular Brain Research · doi:10.1016/0169-328x(95)00097-c · Cited by 210
APOE ε4 Genotype and Longitudinal Changes in Cerebral Blood Flow in Normal Aging
Thambisetty, M., Beason-Held, L., An, Y., Kraut, M. A., & Resnick, S. M. (2010) · Archives of Neurology · doi:10.1001/archneurol.2009.913 · Cited by 209
Chen, H.-K., Ji, Z.-S., Dodson, S. E., Miranda, R. D., Rosenblum, C. I., Reynolds, I. J., Freedman, S. B., Weisgraber, K. H., Huang, Y., & Mahley, R. W. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.151084 · Cited by 209
Serum MCP-1 levels are increased in mild cognitive impairment and mild Alzheimer’s disease
Galimberti, D., Fenoglio, C., Lovati, C., Venturelli, E., Guidi, I., Corrà, B., Scalabrini, D., Clerici, F., Mariani, C., Bresolin, N., et al. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.10.007 · Cited by 209
Rogalski, E. J., Gefen, T., Shi, J., Samimi, M., Bigio, E., Weintraub, S., Geula, C., & Mesulam, M.-M. (2013) · Journal of Cognitive Neuroscience · doi:10.1162/jocn_a_00300 · Cited by 196
“Overwhelming evidence supports the conclusion that the ε4 allele increases the risk of Alzheimerʼs disease by shifting the age-incidence curve to the left, as if it promoted earlier disease onset (Corder et al., 1993; Poirier et al., 1993).”
BackgroundReplication of CLU, CR1, and PICALM Associations With Alzheimer Disease
Carrasquillo, M. M., Belbin, O., Hunter, T. A., Ma, L., Bisceglio, G. D., Zou, F., Crook, J. E., Pankratz, V. S., Dickson, D. W., Graff-Radford, N. R., et al. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.147 · Cited by 208
“Until recently, however, APOE ε4 was the only allele reliably associated with increased susceptibility to LOAD.(3-5) A robust technology has emerged that permits genome-wide association studies (GWAS) of large numbers of subjects.”
Molecular biology and genetics of Alzheimer's disease
St George-Hyslop, P. H., & Petit, A. (2005) · Comptes Rendus. Biologies · doi:10.1016/j.crvi.2004.10.013 · Cited by 210
Burt, T. D., Agan, B. K., Marconi, V. C., He, W., Kulkarni, H., Mold, J. E., Cavrois, M., Huang, Y., Mahley, R. W., Dolan, M. J., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803526105 · Cited by 205
Emrani, S., Arain, H. A., DeMarshall, C., & Nuriel, T. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00712-4 · Cited by 194
“more, while possession of the APOE2 allele is protective against AD [2, 10, 11], with Caucasian individuals who”
BackgroundApolipoprotein E and cognitive change in an elderly population
Hyman, B. T., Gomez‐Isla, T., Briggs, M., Chung, H., Nichols, S., Kohout, F., & Wallace, R. (1996) · Annals of Neurology · doi:10.1002/ana.410400111 · Cited by 205
Dodart, J.-C., Marr, R. A., Koistinaho, M., Gregersen, B. M., Malkani, S., Verma, I. M., & Paul, S. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409072102 · Cited by 207
Lo Sasso, G., Schlage, W. K., Boué, S., Veljkovic, E., Peitsch, M. C., & Hoeng, J. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-0901-1 · Cited by 187
“On the contrary, the ε4 allele has been associated with CHD [47], Alzheimer’s disease [56], age-related cognitive decline [57], and other diseases [58].”
BackgroundRahman, A., Jackson, H., Hristov, H., Isaacson, R. S., Saif, N., Shetty, T., Etingin, O., Henchcliffe, C., Brinton, R. D., & Mosconi, L. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00315 · Cited by 187
Downregulation of microglial activation by apolipoprotein E and apoE-mimetic peptides
Laskowitz, D. T., Thekdi, A. D., Thekdi, S. D., Han, S. K. D., Myers, J. K., Pizzo, S. V., & Bennett, E. R. (2001) · Experimental Neurology · doi:10.1006/exnr.2001.7541 · Cited by 206
Ancestral origin of ApoE ε4 Alzheimer disease risk in Puerto Rican and African American populations
Rajabli, F., Feliciano, B. E., Celis, K., Hamilton-Nelson, K. L., Whitehead, P. L., Adams, L. D., Bussies, P. L., Manrique, C. P., Rodriguez, A., Rodriguez, V., et al. (2018) · PLOS Genetics · doi:10.1371/journal.pgen.1007791 · Cited by 206
Self-citationPericak-Vance, M. A. (1997) · JAMA · doi:10.1001/jama.1997.03550150041033 · Cited by 206
Self-citationNebel, A., Kleindorp, R., Caliebe, A., Nothnagel, M., Blanché, H., Junge, O., Wittig, M., Ellinghaus, D., Flachsbart, F., Wichmann, H.-E., et al. (2011) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2011.06.008 · Cited by 200
“008 that predisposes to both Alzheimer’s and cardiovascular diseases (Corder et al., 1993; Panza et al., 2004).”
InfluentialSwerdlow, R. H. (2012) · Antioxidants & Redox Signaling · doi:10.1089/ars.2011.4149 · Cited by 203
“Apolipoprotein E4 (1-272) fragment is associ-”
Genetic Association Mapping Based on Discordant Sib Pairs: The Discordant-Alleles Test
Boehnke, M., & Langefeld, C. D. (1998) · The American Journal of Human Genetics · doi:10.1086/301787 · Cited by 206
“Increased numbers of the e4 allele result in an increased risk of Alzheimer disease (Corder et al. 1993; Saunders et al. 1993), whereas presence of the e2 allele appears to reduce Alzheimer disease risk (Corder et al.”
BackgroundResultInfluentialRamanathan, A., Nelson, A. R., Sagare, A. P., & Zlokovic, B. V. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00136 · Cited by 205
“Recent studies have evidenced how Aβ clearance mechanisms in the CNS are indirectly altered by vascular- and metabolism-related genes via SREBP2-mediated regulation of LRP1 (Figure 3C).”
BackgroundMeftah, S., & Gan, J. (2023) · Frontiers in Synaptic Neuroscience · doi:10.3389/fnsyn.2023.1129036 · Cited by 205
APOE alleles predict the rate of cognitive decline in Alzheimer disease: A nonlinear model
Martins, C. A. R., Oulhaj, A., de Jager, C. A., & Williams, J. H. (2005) · Neurology · doi:10.1212/01.wnl.0000188871.74093.12 · Cited by 205
“5) 15 (7) 8 (4) 69 (32) 97 (45) 28 (13)”
Apolipoprotein E4 polymorphism as a genetic predisposition to delirium in critically ill patients*
Ely, W. E., Girard, T. D., Shintani, A. K., Jackson, J. C., Gordon, S. M., Thomason, J. W. W., Pun, B. T., Canonico, A. E., Light, R. W., Pandharipande, P., et al. (2007) · Critical Care Medicine · doi:10.1097/01.ccm.0000251925.18961.ca · Cited by 202
“Although the APOE4 allele has been associated with increased frailty in elderly patients (23, 55), in the current study the APOE4 patients were younger and had no evidence of greater baseline dementia.”
BackgroundThe capillary dysfunction hypothesis of Alzheimer's disease
Østergaard, L., Aamand, R., Gutiérrez-Jiménez, E., Ho, Y.-C. L., Blicher, J. U., Madsen, S. M., Nagenthiraja, K., Dalby, R. B., Drasbek, K. R., Møller, A., et al. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.09.011 · Cited by 199
“However, it is difficult to reconcile this view with the observation of abnormally high CBF levels in asymptomatic carriers of the apolipoprotein E (APOE) ε4 AD risk gene, which is believed to be an important factor in the etiology of more than half of all AD cases (Corder et al., 1993).”
Esiri, M. (2007) · The Journal of Pathology · doi:10.1002/path.2089 · Cited by 180
“ApoE ε2 is protective against AD and ε4 is a risk factor for late-onset AD [71].”
BackgroundCheng, Y., Tian, D.-Y., & Wang, Y.-J. (2020) · Translational Neurodegeneration · doi:10.1186/s40035-020-00195-1 · Cited by 190
“(3) The apolipoprotein E (ApoE) ε4 allele, the strongest genetic risk factor for AD, is closely involved in the regulation of Aβ metabolism [3].”
Apolipoprotein E4 Forms a Molten Globule
Morrow, J. A., Hatters, D. M., Lu, B., Höchtl, P., Oberg, K. A., Rupp, B., & Weisgraber, K. H. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m204898200 · Cited by 204
Molecular Mechanisms and Genetics of Oxidative Stress in Alzheimer’s Disease
Cioffi, F., Adam, R. H. I., & Broersen, K. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190863 · Cited by 204
“Carriers of the 4-allele have an increased risk of developing AD [236] as well as a decreased age of AD onset [237] compared to non- 4 carriers.”
BackgroundRuiz, J., Kouiavskaia, D., Migliorini, M., Robinson, S., Saenko, E. L., Gorlatova, N., Li, D., Lawrence, D., Hyman, B. T., Weisgraber, K. H., et al. (2005) · Journal of Lipid Research · doi:10.1194/jlr.m500114-jlr200 · Cited by 204
“Second, the APOE- 4 allele is associated with the common late-onset familial and sporadic forms of Alzheimer’s disease (AD) (7, 8).”
BackgroundCastaño, E. M., Roher, A. E., Esh, C. L., Kokjohn, T. A., & Beach, T. (2006) · Neurological Research · doi:10.1179/016164106x98035 · Cited by 201
Is Alzheimer disease a disease?
Korczyn, A. D., & Grinberg, L. T. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-024-00940-4 · Cited by 189
“For instance, carrying the APOE4 haplotype has been known to be a significant risk factor for LOAD for the past 30 years 49 , suggesting that directing interventions towards APOE4 could potentially serve as a treatment strategy for individuals within this group.”
The Role of Heredity in Late-Onset Alzheimer Disease and Vascular Dementia: A Twin Study
Bergem, A. L. M. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830150090013 · Cited by 206
The clinical introduction of genetic testing for Alzheimer disease. An ethical perspective
Post, S. G. (1997) · JAMA · doi:10.1001/jama.277.10.832 · Cited by 176
Østergaard, S. D., Mukherjee, S., Sharp, S. J., Proitsi, P., Lotta, L. A., Day, F., Perry, J. R. B., Boehme, K. L., Walter, S., Kauwe, J. S., et al. (2015) · PLOS Medicine · doi:10.1371/journal.pmed.1001841 · Cited by 203
“Rather, the well-established association of APOE haplotypes with AD risk [47] implicates APOE itself as a key causal factor in the etiology of AD.”
Oxidative imbalance in patients with mild cognitive impairment and Alzheimer’s disease
GUIDI, I., GALIMBERTI, D., LONATI, S., NOVEMBRINO, C., BAMONTI, F., TIRITICCO, M., FENOGLIO, C., VENTURELLI, E., BARON, P., & BRESOLIN, N. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.01.001 · Cited by 203
“The correlation with age, gender, mini mental state examination (MMSE) score, age at onset, duration of the disease and with the presence of the ApoE 4 allele, a major genetic risk factor for sporadic AD [7], was also analyzed in the same groups of patients in order to verify the relationship of these factors with the…”
BackgroundHuebbe, P., & Rimbach, G. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2017.06.002 · Cited by 195
The Role of APOE and TREM2 in Alzheimer′s Disease—Current Understanding and Perspectives
Wolfe, C. M., Fitz, N. F., Nam, K. N., Lefterov, I., & Koldamova, R. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms20010081 · Cited by 187
“APOEε4 and TREM2-R47H variant were identified as independent risk factors for LOAD [6,119,120,178].”
BackgroundAPOE4 impairs the microglial response in Alzheimer’s disease by inducing TGFβ-mediated checkpoints
Yin, Z., Rosenzweig, N., Kleemann, K. L., Zhang, X., Brandão, W., Margeta, M. A., Schroeder, C., Sivanathan, K. N., Silveira, S., Gauthier, C., et al. (2023) · Nature Immunology · doi:10.1038/s41590-023-01627-6 · Cited by 222
Fleisher, A. S., Chen, K., Liu, X., Ayutyanont, N., Roontiva, A., Thiyyagura, P., Protas, H., Joshi, A. D., Sabbagh, M., Sadowsky, C. H., et al. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.04.017 · Cited by 202
“Furthermore, the presence of the APOE4 gene hastens the onset of clinical dementia by approximately 10 to 15 years (Corder et al., 1993; Khachaturian et al., 2004; Meyer et al., 1998), shifting the onset of amyloid accumulation to an earlier age compared with non-carriers in pathological studies (Kok et al.”
BackgroundCell type‐specific roles of APOE4 in Alzheimer disease
Blumenfeld, J., Yip, O., Kim, M. J., & Huang, Y. (2024) · Nature Reviews Neuroscience · doi:10.1038/s41583-023-00776-9 · Cited by 202
“For late-onset AD, which accounts for the vast majority of AD cases, researchers so far have identified only genetic loci that can alter disease risk, the strongest of which is the apolipoprotein E ( APOE ) locus 9,10 .”
Seshadri, S., DeStefano, A. L., Au, R., Massaro, J. M., Beiser, A. S., Kelly-Hayes, M., Kase, C. S., D'Agostino, R. B., DeCarli, C., Atwood, L. D., et al. (2007) · BMC Medical Genetics · doi:10.1186/1471-2350-8-s1-s15 · Cited by 199
“However, surprisingly few genes have been identified that determine the risk of developing stroke (PDE4D, ALOX5AP) [9-11] or Alzheimer's disease (APOE4) [12], in the community as a whole, that is for persons not from autosomal dominant, early-onset families.”
Introduction of human apolipoprotein E4 “domain interaction” into mouse apolipoprotein E
Raffaï, R. L., Dong, L.-M., Farese, R. V., & Weisgraber, K. H. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.201279298 · Cited by 194
Correia, S. C., Santos, R. X., Carvalho, C., Cardoso, S., Candeias, E., Santos, M. S., Oliveira, C. R., & Moreira, P. I. (2012) · Brain Research · doi:10.1016/j.brainres.2011.12.063 · Cited by 195
Chronic Traumatic Encephalopathy: The Neuropathological Legacy of Traumatic Brain Injury
Hay, J., Johnson, V. E., Smith, D. H., & Stewart, W. (2016) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012615-044116 · Cited by 192
The Women's Health Initiative Memory Study: findings and implications for treatment
Craig, M., Maki, P. M., & Murphy, D. (2005) · The Lancet Neurology · doi:10.1016/s1474-4422(05)01016-1 · Cited by 197
The Pathogenesis of Alzheimers Disease—Is It a Lifelong “Calciumopathy”?
Stutzmann, G. E. (2007) · The Neuroscientist · doi:10.1177/1073858407299730 · Cited by 195
Evidence-Based Review of Sport-Related Concussion: Basic Science
McCrory, P., Johnston, K. M., Mohtadi, N. G., & Meeuwisse, W. (2001) · Clinical Journal of Sport Medicine · doi:10.1097/00042752-200107000-00006 · Cited by 201
Weksler, M. E., Relkin, N., Turkenich, R., LaRusse, S., Zhou, L., & Szabo, P. (2002) · Experimental Gerontology · doi:10.1016/s0531-5565(02)00029-3 · Cited by 201
Ramanan, V. K., Risacher, S. L., Nho, K., Kim, S., Swaminathan, S., Shen, L., Foroud, T. M., Hakonarson, H., Huentelman, M. J., Aisen, P. S., et al. (2014) · Molecular Psychiatry · doi:10.1038/mp.2013.19 · Cited by 200
“The strongest known genetic risk factor for AD is presence of the apolipoprotein E ( APOE ) ε 4 allele, 7 and in vitro and murine studies have proposed plausible links between the encoded ApoE E4 isoform and aberrant A β mechanisms.”
Child Development, Molecular Genetics, and What to Do with Genes Once They Are Found
Plotnin, R., & Rutter, M. (1998) · Child Development · doi:10.1111/j.1467-8624.1998.tb06169.x · Cited by 148
Convergent genetic and expression data implicate immunity in Alzheimer's disease
International Genomics of Alzheimer's Disease Consortium (IGAP), Jones, L., Lambert, J., Wang, L., Choi, S., Harold, D., Vedernikov, A., Escott‐Price, V., Stone, T., Richards, A., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.05.1757 · Cited by 199
“In the Genetic and Environmental Risk in Alzheimer’s Disease data set [8], approximately 20% of the total trait variance was accounted for by singlenucleotide polymorphisms (SNPs) on the GWAS chip outside the APOE region [9], with the ε4 allele of the APOE gene [10] accounting for a similar amount [9,11].”
Reduced Hippocampal Volume in Healthy Young ApoE4 Carriers: An MRI Study
O'Dwyer, L., Lamberton, F., Matura, S., Tanner, C., Scheibe, M., Miller, J., Rujescu, D., Prvulovic, D., & Hampel, H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048895 · Cited by 192
“There are three allelic variants of the ApoE gene in humans (E2, E3, E4) [5] with the E4 allele consistently being shown to confer a higher risk of developing both early and late onset Alzheimer’s disease (AD) [6,7].”
BackgroundWashington, P. M., Villapol, S., & Burns, M. P. (2016) · Experimental Neurology · doi:10.1016/j.expneurol.2015.06.015 · Cited by 189
“The APOE4 gene alone increases the risk of developing AD (Corder et al., 1993) and the synergistic interaction of TBI and APOE4 together increases the risk of developing AD above predicted levels (Mayeux et al.”
BackgroundSchaefer, E. J., Lamon-Fava, S., Johnson, S., Ordovas, J. M., Schaefer, M. M., Castelli, W. P., & Wilson, P. W. (1994) · Arteriosclerosis and Thrombosis: A Journal of Vascular Biology · doi:10.1161/01.atv.14.7.1105 · Cited by 202
Simpson, J. E., Ince, P. G., Shaw, P. J., Heath, P. R., Raman, R., Garwood, C. J., Gelsthorpe, C., Baxter, L., Forster, G., Matthews, F. E., et al. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.04.013 · Cited by 192
Näslund, J., Thyberg, J., Tjernberg, L. O., Wernstedt, C., Karlström, A. R., Bogdanovic, N., Gandy, S. E., Lannfelt, L., Terenius, L., & Nordstedt, C. (1995) · Neuron · doi:10.1016/0896-6273(95)90079-9 · Cited by 189
Overweight in midlife and risk of dementia: a 40-year follow-up study
Hassing, L. B., Dahl, A. K., Thorvaldsson, V, Berg, S., Gatz, M., Pedersen, N. L., & Johansson, B. (2009) · International Journal of Obesity · doi:10.1038/ijo.2009.104 · Cited by 197
Glial Lipoproteins Stimulate Axon Growth of Central Nervous System Neurons in Compartmented Cultures
Hayashi, H., Campenot, R. B., Vance, D. E., & Vance, J. E. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313828200 · Cited by 191
Early detection of Alzheimer’s disease using neuroimaging
Mosconi, L., Brys, M., Glodzik-Sobanska, L., De Santi, S., Rusinek, H., & de Leon, M. J. (2007) · Experimental Gerontology · doi:10.1016/j.exger.2006.05.016 · Cited by 187
Espinosa, A., Alegret, M., Valero, S., Vinyes-Junqué, G., Hernández, I., Mauleón, A., Rosende-Roca, M., Ruiz, A., López, O., Tárraga, L., et al. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-122002 · Cited by 183
“Interestingly, there were no MCI subjects with the ε2/ε2 haplotype, which has been related to protection against late-onset AD [47].”
Background
Metadata
- Authors
- Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A.
- Affiliations
- Duke University (US)
- Duke Medical Center (US)
- University of California, Los Angeles (US)
- Massachusetts General Hospital (US)
- Joseph and Kathleen Bryan Alzheimer's Disease Research Center, Duke University Medical Center, Durham, NC 27710.
- Venue
- Science
- Published
- 1993-08-13
- Volume
- 261
- Issue
- 5123
- Pages
- 921-923
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2036362108
- Cited by
- 9,429
- References
- 16
- Citations by year
- 2026: 289 · 2025: 380 · 2024: 355 · 2023: 328 · 2022: 356 · 2021: 378 · 2020: 396 · 2019: 358 · 2018: 341 · 2017: 343 · 2016: 345 · 2015: 303 · 2014: 343 · 2013: 335 · 2012: 333
- FWCI
- 135.93
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- apolipoprotein E, APOE ε4, gene dosage, Alzheimer's disease, genetic risk, homozygosity, age of onset, genetic association
- MeSH terms
- Aged, Aged, 80 and over, Aging, Alleles, Alzheimer Disease, Apolipoproteins E, Female, Gene Frequency, Genotype, Homozygote, Humans, Male, Risk Factors, Linkage Disequilibrium, Survival Rate, Amyloid beta-Peptides, Apolipoprotein E4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.